skip to Main Content

Submitted Case

2022
1. Submitted Case
2. Submitted Case
3. Submitted Case
4. Peer Review
5. Submitted Case
6. Submitted Case
7. Submitted Case
8. Submitted Case
9. Peer Review
10. Submitted Case
11. Submitted Case
12. Submitted Case
13. Submitted Case
14. Submitted Case
15. Submitted Case
16. Submitted Case
17. Submitted Case
18. Submitted Case
19. Submitted Case
20. Submitted Case
21. Submitted Case
22. Submitted Case
23. Submitted Case
24. Submitted Case
25. Submitted Case
26. Submitted Case
27. Submitted Case
28. Submitted Case
29. Submitted Case
30. Submitted Case
31. Submitted Case
32. Peer Review
33. Peer Review
34. Peer Review
35. Peer Review
36. Peer Review
37. Submitted Case
38. Submitted Case
39. Submitted Case
40. Peer Review
41. Submitted Case
42. Peer Review
43. Submitted Case
44. Submitted Case
Patient Information: (Do not provide name of the patient)
Age
  57
Diagnosis
  Regional N1 prostate cancer
Imaging
  CT A/P pre/post ADT, Bone scan
Pathology
  adenocarcinoma, iPSA 97, Gleason score 5+4=9, 12/12+ cores, PCI 90%
Stage
  IVA
Overall Oncology Management Plan
Surgery (biopsy)
  Biopsy as above
Chemotherapy (if given, what is the regimen)
  None
Hormone Therapy
  Casodex, Lupron, Abitaretarone/prednisone X 6 mo
Radiation Therapy (fields, dose)
  Pelvis to 45/25 -> LAD/prostate/pSV 9/5 -> prostate/pSV 27/15 (total 81Gy/45Fx sequential boosts)
Radiation Treatment Plan
Defining target and margin
  CTV_4500: pelvic LNs, prostate, SVs; CTV_5400:GTVn+5mm, prostate, prox SV; CTV_8100: prostate, prox SVs; PTV=CTV+5mm (CBCT daily)
Normal Tissue Sparing
  As per NRG GU007
Dose/fractionation
  81Gy/45Fx
Images
Session Name
  GU Specialist Dr. Howard Sandler- August 9, 2022
Session ID
  12181
created_by
  8517
post_id
  12181
Back To Top